Phyllodes Tumors: A Scoping Review of the Literature

Bogach, Jessica; Shakeel, Saad; Wright, Frances C.; Hong, Nicole J. Look

doi:10.1245/s10434-021-10468-2

Cited by 27 publications

(39 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…al reportan una tasa de recurrencia de 4% con cualquier enfermedad benigna (n: 1578) después del tratamiento con UGVAB. Park y colaboradores reportaron una tasa de 3,2% de recurrencia para 53 pacientes con TP benigno después de UGVAB, los pacientes tenían tumores menores de 3 cm y un seguimiento de 24 meses (1,12) .…”

Section: Biopsia Por Aspiración Al Vacío Guiada Por Ecografía (Ugvab)unclassified

“…Los factores asociados con una pobre sobrevida global (OS) en el análisis univariado fueron: la edad > 50 años, el diagnóstico de TP maligno en la biopsia preoperatoria, la presencia de metástasis al momento del diagnóstico, recurrencia metastásica y 0/1/2 mm de margen sin SS (1,5) . Una segunda cirugía (SS) para obtener márgenes libres provee LRFS, MFS y OS idénticas a los casos con cirugía óptima de inicio.…”

Section: Tratamiento Con Quimioterapia Y Radioterapiaunclassified

“…Se encontró un beneficio de la radioterapia en términos de LRFS en el análisis univariado, la radioterapia fue propuesta en pacientes con grandes tumores, ulcerados, necróticos. La quimioterapia también fue indicada en tumores grandes y necróticos y no se correlacionó con la sobrevida, como se documenta en estudios previos (1,5) .…”

Section: Tratamiento Con Quimioterapia Y Radioterapiaunclassified

“…5 cm y/o el efecto estético no es óptimo (por ejemplo: mamas pequeñas) se recomienda la mastectomía total sin evaluación quirúrgica de la región axilar por el bajo compromiso de los ganglios linfáticos. La OMS reporta recurrencia local para TP benignos en un rango de 10-17%, 14-25% para TP borderline y 23-30% para TP malignos (1,4) . El efecto de la quimioterapia adyuvante no es claro.…”

Section: Artículo De Revisiónunclassified

See 3 more Smart Citations

Tumor Phyllodes de la mama

et al. 2022

Interciencia méd.

View full text Add to dashboard Cite

Introducción: El tumor phyllodes (TP) es un tumor raro de la mama, representa menos del 1% de todas las neoplasias de la mama (1) y el 2 a 3 % de los tumores fibroepiteliales (7). Esta neoplasia se clasifica en: TP Benigno, TP Borderline y TP Maligno (Norris y Taylor-OMS) (9). Objetivo: Realizar una revisión acerca del diagnóstico y tratamiento del tumor phyllodes. Desarrollo: Los TP son neoplasias fibroepiteliales qué de acuerdo a la celularidad estromal, atipia nuclear, tasa mitótica, elementos heterólogos son clasificados como: benignos, borderline y malignos (1). La máxima incidencia se da entre los 35-55 años. El diagnóstico por imágenes se basa en el uso de mamografía, ecografía, resonancia magnética y biopsia core radioguiada. El óptimo manejo quirúrgico constituye la herramienta fundamental en TP. Existe controversia acerca del uso de tratamiento adyuvante con radioterapia y quimioterapia. Conclusiones: TP es una neoplasia benigna de la mama, la cirugía es el tratamiento de elección. El borde libre mayor de 1 cm recomendado por la NCCN es predictivo para un menor porcentaje de recurrencia local. Los tratamientos complementarios con radioterapia y quimioterapia son controversiales.

show abstract

Section: Biopsia Por Aspiración Al Vacío Guiada Por Ecografía (Ugvab)unclassified

Section: Tratamiento Con Quimioterapia Y Radioterapiaunclassified

Section: Artículo De Revisiónunclassified

See 2 more Smart Citations

Tumor Phyllodes de la mama

et al. 2022

Interciencia méd.

View full text Add to dashboard Cite

show abstract

“…Phyllodes tumors are a rare type of fibroepithelial neoplasms of the breast typically occurring in women of ages 35-55 years, and accounting for approximately 0.3-0.9% of all primary breast neoplasms [1][2][3][4][5][6][7]. Phyllodes tumors and fibroadenomas are both included in the category of biphasic fibroepithelial lesions of the breast; fibroadenomas are far more common in clinical practice and constitute the majority of benign breast masses in younger women [2,[7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Giant Phyllodes Tumor in an 82-Year-Old Female Initially Diagnosed a Fibroadenoma: A Case Report

Hefelfinger¹,

Hefelfinger²,

Hernandez³

2022

Cureus

View full text Add to dashboard Cite

Phyllodes tumors are a rare fibroepithelial neoplasm of the breast occurring in approximately 2.1 in every 1 million women with no clear predilection for women of specific races. They are characterized by spindleshaped stromal cells with increased stromal cellularity and increased mitotic activity. The histologic characteristics are similar to that of cellular fibroadenomas making them frequently difficult to differentiate on core biopsy. We present a case of an 82-year-old female with a right breast mass which was initially diagnosed as a fibroadenoma in 2009. She was lost to follow-up and presented in 2021 with complaint of a right breast mass for which diagnostic imaging was performed. A diagnostic mammogram demonstrated a macrolobulated mass measuring 14×12×12 cm which corresponded to the palpable abnormality. The patient subsequently underwent simple mastectomy demonstrating a 14 cm mass with a fibroepithelial structure consistent with a borderline phyllodes tumor. The patient received adjuvant radiotherapy to minimize the likelihood of local recurrence. We concluded that reliable preoperative diagnosis and further studies regarding guidelines for adequate tumor margins and indication for adjuvant radiotherapy are crucial for proper surgical planning and follow-up after excision.

show abstract

Clinical outcomes and biomarkers of phyllodes tumors of the breast: A single‐center retrospective study

Chen

Wang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Purpose: Phyllodes tumors (PTs) are rare neoplasms with a certain risk of recurrence and/or metastasis. In clinical practice, there is a lack of high-quality clinical studies and unified guidelines to guide the treatment. Materials and Methods:All malignant and recurrence/metastasis PTs were retrospectively collected, which were diagnosed from 2008 to 2022.Results: A total of 82 patients were enrolled, including 69 malignant and 13 borderline tumors. 96.3% (79/82) received surgical treatment. During a median follow-up of 55.5 months, 20 patients (20/82, 24.4%) had distant metastasis (DM), while 32 (32/82, 39.0%) had local recurrence (LR). Univariate analysis showed the survival of PTs was associated with surgical methods (p < 0.001), tumor size (p = 0.026), and biological behavior (p = 0.017), but not age at diagnosis. In relapsed borderline PTs, we did not find deaths due to disease progression. Patients with DM were all malignant PTs, with disease-progression occurring within 3 years in more than 80% of patients. Among salvage treatments, the combination of antiangiogenic drugs improved the prognosis to some extent, with a significant increase in mPFS (2.77 vs. 1.53 months), but no significant statistical results were obtained (p = 0.168). Lactate dehydrogenase (LDH) was an independent predictor of the prognosis for malignant PTs (p = 0.001, HR = 1.203, 95%CI, 1.082-1.336). Conclusion: Borderline PTs rarely metastasize, and even if LR occurs, surgical resection can lead to long-term survival. In metastatic phyllodes tumors (MPT), systemic therapy is not effective, but antiangiogenic drugs may prolong survival.LDH is an independent prognostic factor for malignant PTs to identify high-risk tumors.

show abstract

Phyllodes Tumors: A Scoping Review of the Literature

Cited by 27 publications

References 123 publications

Tumor Phyllodes de la mama

Tumor Phyllodes de la mama

Giant Phyllodes Tumor in an 82-Year-Old Female Initially Diagnosed a Fibroadenoma: A Case Report

Clinical outcomes and biomarkers of phyllodes tumors of the breast: A single‐center retrospective study

Contact Info

Product

Resources

About